ACTRN12614001311640进行中（未招募）未知
A Phase III randomised, controlled trial to evaluate the effect of exercise during chemotherapy on progression-free survival and physical well-being in patients commencing first line treatment for ovarian cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 524
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •1.Women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer of any histological type, suitable for first-line chemotherapy
- •2.Age > or = 18 years
- •3.ECOG status 0-2
- •4.Willing and able to comply with all study requirements, including the exercise intervention, timing and/or nature of required assessments
- •5.Sufficiently fluent in English to fully participate in data collection requirements and comprehend intervention requirements
- •6.Scheduled for chemotherapy or has commenced chemotherapy. Participants must be enrolled prior to commencement of the 2nd cycle of chemotherapy
- •7.Signed written informed consent
排除标准
- •1.Women with diagnosis of recurrent ovarian cancer
- •2.History of another malignancy within 3 years prior to registration. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, Stage I melanoma in situ or superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least 3 years after definitive primary treatment.
- •3.Concurrent illness, including severe infection or unstable angina that may jeopardise the ability of the patient to undergo the exercise intervention outlined in this protocol with reasonable safety.
- •4.Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.
研究者
相似试验
进行中（未招募）
不适用
A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine and to evaluate the non-inferiority to Prevenar™ in a single blind design, when administered as a 3-dose primary immunization course before 6 months of age. - 10PN-PD-DIT-001EUCTR2005-003300-11-FIGlaxoSmithKline Biologicals1,600
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 14.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-FRAGO Research GmbH796
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 19.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-DKAGO Research GmbH796
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-DEAGO Research GmbH900
进行中（未招募）
1 期
The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) TrialEpithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, FIGO Stages IIb-IVMedDRA version: 14.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-FIJohanna Mäenpää796